Last reviewed · How we verify
CHF1535 pMDI
CHF1535 pMDI is a corticosteroid inhalation powder.
CHF1535 pMDI is a corticosteroid inhalation powder. Used for Maintenance and relief of asthma symptoms, Maintenance treatment of COPD symptoms.
At a glance
| Generic name | CHF1535 pMDI |
|---|---|
| Also known as | Foster |
| Sponsor | Chiesi Farmaceutici S.p.A. |
| Drug class | Corticosteroid |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | Phase 2 |
Mechanism of action
It works by reducing inflammation in the lungs to control symptoms of asthma and COPD.
Approved indications
- Maintenance and relief of asthma symptoms
- Maintenance treatment of COPD symptoms
Common side effects
- Oral thrush
- Hoarseness
- Cough
Key clinical trials
- Study in Adult Patients With Moderate to Severe Asthma (PHASE3)
- Efficacy and Safety of CHF 1535 200/6µg in Not Adequately Controlled Asthmatic Patients (PHASE3)
- A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (PHASE3)
- A Study Testing the Superiority of CHF 1535 pMDI 800/24µg Total Daily Dose Compared With CHF 718 pMDI 800µg Total Daily Dose in Adults With Asthma on Medium or High-Dose Inhaled Corticosteroid (PHASE3)
- Foster® pMDI (CHF 1535) Versus Symbicort® Turbohaler in COPD Patient (PHASE3)
- Step-up to Medium Strength Triple Therapy vs High Strength ICS/LABA in Adult Asthmatics Uncontrolled on Medium Strength ICS/LABA (PHASE4)
- CHF5993 and CHF1535 pMDI on Lung Hyperinflation and Exercise Endurance Time in Subjects With COPD (PHASE4)
- A Phase II, 5-way Cross-over Study to Evaluate the Pharmacodynamics of "Nexthaler" Dry Powder Inhaler in COPD Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CHF1535 pMDI CI brief — competitive landscape report
- CHF1535 pMDI updates RSS · CI watch RSS
- Chiesi Farmaceutici S.p.A. portfolio CI